Bielecka-Dabrowa A, Banach M, Wittczak A, Cicero AFG, Kallel A, Kubilius R, Mikhailidis DP, Sahebkar A, Pantea Stoian A, Vinereanu D, Penson PE, von Haehling S.
Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, Paneni F, Parini P, Pirro M, Reiner Ž, Vrablik M, Escobar C.
Banach M, Cannon CP, Paneni F, Penson PE; endorsed by the International Lipid Expert Panel (ILEP).
Rizzo M, Colletti A, Penson PE, Katsiki N, Mikhailidis DP, Toth PP, Gouni-Berthold I, Mancini J, Marais D, Moriarty P, Ruscica M, Sahebkar A, Vinereanu D, Cicero AFG, Banach M; International Lipid Expert Panel (ILEP)
Statins are a widely available, cheap, safe, and extremely effective means to reduce the cardiovascular disease (CVD) risk, and it is therefore a tragedy that these life-saving medicines are under-used. Non-adherence to statin therapy reaches up to 60% after 2 years, and cessation is associated with a significant increase in the risk of CVD events. Much of this […]
Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many […]
Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially ameliorates the risk and is associated with long-term reduction in cardiovascular (CV) events. The robust evidence supporting these therapies supports their continued (and expanding) role in risk reduction. In addition […]
Abstract Aims Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different […]
https://ilep.eu/wp-content/movies/20221008082604_live7603_2022-10-08-07.47.08.515-UTC.mp4
Banach M, Catapano AL, Cicero AFG, Escobar C, Foger B, Katsiki N, Latkovskis G, Rakowski M, Reiner Z, Sahebkar A, Sikand G, Penson PE, On Behalf Of The International Lipid Expert Panel Ilep.